Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
20180146
Phase 1 other active
Quick answer
Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer for Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Phase
- Phase 1
- Modality
- other
- Status
- active